Precision Medicine in Diabetes: Beyond One-Size-Fits-All

Precision medicine in diabetes is not mainly about genome sequencing. In practice it means a simpler and harder thing: matching the right care to the right person, at the right moment, instead of treating everyone with the same diagnosis the same way. The genetics matter, and I have spent years studying them. But the day-to-day promise of precision medicine is that two people who both carry the label "type 2 diabetes" might need very different things, and that the system around them should be able to tell the difference.

That sounds obvious. It is not how most care works. A guideline is built on the average patient, and the average patient is a statistical fiction. Real people sit somewhere on a wide distribution, and a meaningful number of them sit at the edges, where the average advice fits badly or not at all.

Why averages fail people at the edges

Type 2 diabetes is not one disease. It is a label we hang on a group of conditions that happen to share a symptom: blood glucose that runs too high. Underneath that label, the biology varies a lot. Some people are mostly insulin resistant. Others have beta cells that are failing to keep up. Some have a strong genetic load that showed up early, before the usual lifestyle story applies. The same number on a lab report can come from very different machinery.

This is where my research lives. Work I contributed to on the genetics of type 2 diabetes, including a paper in Science on how overexpression of alpha2A-adrenergic receptors contributes to the disease, points at one specific mechanism in insulin secretion. It is a reminder that "high glucose" is a final common output of many different upstream faults. A drug that helps one mechanism can do little for another.

The edges matter for another reason, and it is one I keep coming back to. A systematic review and meta-analysis I co-authored in Diabetes Care looked at ethnic differences in the relationship between insulin sensitivity and insulin response. The short version is that the link between how sensitive you are to insulin and how much your body releases is not identical across populations. If your risk model was tuned on one group and applied to another, it can quietly misjudge people. The average was never neutral. It carried the shape of whoever happened to be in the dataset.

When you average across all of that, you get advice that is correct for the middle and wrong for the tails. The person at the tail is not an outlier to be ignored. They are a patient with a name.

What precision actually looks like in the clinic

Precision medicine gets sold as a future of genomic dashboards. The more honest version is less futuristic and more useful. It is using the information you already have, more of it and more carefully, to choose among existing options.

That means looking at the pattern of someone's glucose over time rather than a single fasting number. It means weighing their other conditions, their kidney function, their weight trajectory, what they can actually sustain, and what has already failed for them. Most of this data exists. The problem is rarely that we lack information. It is that a busy clinician, in a short appointment, cannot hold all of it in working memory at once and compare it against everything the literature now says.

This is the practical case for clinical decision support, and it is the problem I worked on directly. I co-developed EASY Diabetes, an AI based decision-support system for type 2 diabetes, built together with patients, clinicians, and researchers. The point of a tool like that is not to replace judgment. It is to hold the nuance so the clinician does not have to carry all of it unaided: to surface the relevant guideline, flag the contraindication, and notice the pattern that suggests this patient is not behaving like the average. Its multi-clinic randomized controlled trial, EASY-1 (NCT03258268), evaluated it against standard of care. Efficiency matters as much as accuracy here. Nuance that takes too long to apply does not get applied.

Good decision support also has to know when it is uncertain. A system that confidently gives the average answer to an edge-case patient has reproduced the original problem in software. The harder engineering is building tools that can represent "this person does not fit the usual pattern, look closer" rather than smoothing every case toward the mean.

The honest limits

Precision medicine is not a promise that everyone gets a bespoke molecule. For most people with diabetes, the gains come from better matching among proven treatments, earlier detection of the people heading for trouble, and care that adapts as their disease changes. It also depends on data that is representative, because a model trained on a narrow population will be precise and wrong for everyone it never saw.

This article is educational and is not medical advice. If you are managing diabetes, decisions about your treatment belong with you and your own clinician, who knows your full history.

The goal is modest when you state it plainly, and ambitious when you try to deliver it. See the person, not just the diagnosis. Then build the tools that let an overstretched health system do that at scale, for the patient in the middle and the patient at the edge alike.